Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 28:17:505-512.
doi: 10.17179/excli2017-978. eCollection 2018.

Prognostic significance of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioma

Junli Wang  1 , Wenjing Xiao  2 , Wanyi Chen  3 , Yonghe Hu  2
Affiliations

Prognostic significance of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioma

Junli Wang et al. EXCLI J. .

Abstract

The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been recognized as inflammatory markers and used as prognostic makers in various cancers. The present study sought to investigate the prognostic role of NLR and PLR in Chinese patients with glioma. Clinical data, including NLR, PLR and overall survival (OS), were collected from 112 patients who underwent surgery to treat primary glioma. Kaplan-Meier survival analysis as well as uni- and multivariate Cox regression were performed to examine potential associations of preoperative NLR and PLR with OS. Among all patients, mean NLR was 3.80±1.48 and mean PLR was 183.60±81.38. NLR increased with increasing WHO tumor grade (p < 0.05), but PLR did not (p > 0.05). Patients with NLR ≥ 4 had significantly shorter mean OS (20.75±7.68 months) than patients with NLR < 4 (26.91±7.50 months; p < 0.001). Similarly, patients with PLR ≥ LR had significantly shorter OS than patients with PLR < 200 (p = 0.007). Univariate Cox analysis identified the following parameters as significantly associated with worse OS: NLR (≥ 4), PLR (> 200), tumor size (≥ 5 cm), WHO grade (III/IV), and Karnofsky Performance Status (< 70). Multivariate analysis identified only NLR > 4 as an independent predictor of OS (HR 1.932, 95 % CI 1.011 to 3.694, p = 0.046). Our results suggest that at least in Chinese patients, increased preoperative NLR and PLR are associated with worse OS, and NLR may be an independent risk factor to identify glioma patients with poor prognosis. These results should be validated and extended in larger clinical studies.

Keywords: glioma; neutrophil to lymphocyte ratio; platelet to lymphocyte ratio; prognosis.

PubMed Disclaimer

Figures

Table 1
Table 1. Clinical characteristics of Chinese glioma patients
Table 2
Table 2. Uni- and multivariate Cox regression analysis of factors affecting overall survival
Figure 1
Figure 1. NLR and PLR in glioma patients stratified by WHO grade
(A) NLR increased with increasing WHO grade (p < 0.001). (B) PLR showed a tendency to increase with WHO grade (p = 0.055). NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; WHO: World Health Organization
Figure 2
Figure 2. Kaplan-Meier analysis of overall survival of glioma patients stratified by NLR
NLR: Neutrophil-to-lymphocyte ratio
Figure 3
Figure 3. Kaplan-Meier analysis of overall survival of glioma patients stratified by PLR
NLR: Neutrophil-to-lymphocyte ratio
See this image and copyright information in PMC

References

    1. Auezova R, Ryskeldiev N, Doskaliyev A, Kuanyshev Y, Zhetpisbaev B, Aldiyarova N, et al. Association of preoperative levels of selected blood inflammatory markers with prognosis in gliomas. OncoTargets Ther. 2016;9:6111–6117. - PMC - PubMed
    1. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–249. - PubMed
    1. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol. 2013;114:149–154. - PubMed
    1. Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev. 2017;40:1–14. - PubMed
    1. Conti A, Gulì C, La Torre D, Tomasello C, Angileri FF, Aguennouz M. Role of inflammation and oxidative stress mediators in gliomas. Cancers (Basel) 2010;2:693–712. - PMC - PubMed

LinkOut - more resources